(0.34%) 5 117.06 points
(0.33%) 38 365 points
(0.38%) 15 989 points
(-0.97%) $83.04
(5.25%) $2.02
(0.35%) $2 355.40
(0.48%) $27.67
(4.09%) $959.80
(-0.26%) $0.932
(-0.44%) $10.98
(-0.56%) $0.796
(1.66%) $93.40
2 days till quarter result
(bmo 2024-05-01)
Expected move: +/- 14.14%
Live Chart Being Loaded With Signals
NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico...
Stats | |
---|---|
本日の出来高 | 4 935.00 |
平均出来高 | 50 182.00 |
時価総額 | 9.09M |
EPS | $0 ( 2024-02-22 ) |
次の収益日 | ( $0 ) 2024-05-01 |
Last Dividend | $1 728.00 ( 2007-03-28 ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.730 |
ATR14 | $0.0480 (1.05%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-18 | Horowitz Joshua | Buy | 16 438 | Common Stock |
2024-04-18 | Horowitz Joshua | Buy | 0 | Common Stock |
2024-04-18 | Horowitz Joshua | Sell | 0 | Common Stock |
2024-04-01 | Higgins Thomas T | Buy | 469 | Common Stock |
2024-04-01 | Higgins Thomas T | Sell | 74 | Common Stock |
INSIDER POWER |
---|
54.21 |
Last 97 transactions |
Buy: 971 558 | Sell: 254 579 |
NeuroMetrix Inc 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
NeuroMetrix Inc 財務諸表
Annual | 2023 |
収益: | $5.90M |
総利益: | $3.95M (66.89 %) |
EPS: | $-6.27 |
FY | 2023 |
収益: | $5.90M |
総利益: | $3.95M (66.89 %) |
EPS: | $-6.27 |
FY | 2022 |
収益: | $8.26M |
総利益: | $5.75M (69.65 %) |
EPS: | $-4.90 |
FY | 2021 |
収益: | $8.25M |
総利益: | $5.92M (71.75 %) |
EPS: | $-0.342 |
Financial Reports:
No articles found.
NeuroMetrix Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $1 728.00 | 2007-03-28 |
Last Dividend | $1 728.00 | 2007-03-28 |
Next Dividend | $0 | N/A |
Payout Date | 2007-04-13 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $1 728.00 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.01 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2007 | $1.000 | 0.00% |
2008 | $0 | 0.00% |
2009 | $0 | 0.00% |
2010 | $0 | 0.00% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -1.083 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.298 | 1.200 | -9.95 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -0.307 | 1.500 | -4.52 | -6.78 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 16.81 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 14.92 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 1.396 | 1.500 | 3.36 | 5.03 | [0.2 - 2] |
debtRatioTTM | 0.0112 | -1.500 | 9.81 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 52.63 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -3.99 | 2.00 | -1.330 | -2.66 | [0 - 30] |
freeCashFlowPerShareTTM | -4.11 | 2.00 | -2.06 | -4.11 | [0 - 20] |
debtEquityRatioTTM | 0.0120 | -1.500 | 9.95 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.669 | 1.000 | 2.19 | 2.19 | [0.2 - 0.8] |
operatingProfitMarginTTM | -1.212 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -25.26 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.275 | 0.800 | -1.497 | -1.198 | [0.5 - 2] |
Total Score | -0.253 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -1.059 | 1.000 | -0.208 | 0 | [1 - 100] |
returnOnEquityTTM | -0.307 | 2.50 | -2.90 | -6.78 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -4.11 | 2.00 | -1.370 | -4.11 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -3.99 | 2.00 | -1.330 | -2.66 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.0361 | 1.500 | -3.57 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -1.031 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.82 |
NeuroMetrix Inc
NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。